Preclinical pharmacologic studies on 1-nitro-9-(dimethylaminopropylamino)-acridine and its n-oxide. II. Chronic action.
D000166:Acridines / Q000494:pharmacology* / Q000633:toxicity; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000633:toxicity; D001772:Blood Cell Count; D001777:Blood Coagulation / Q000187:drug effects; D004804:Eosinophils; D004906:Erythrocyte Count; D006066:Gonads / Q000187:drug effects; D006321:Heart / Q000187:drug effects; D006454:Hemoglobins / Q000032:analysis; D007422:Intestines / Q000187:drug effects; D007668:Kidney / Q000187:drug effects; D007928:Lethal Dose 50; D007958:Leukocyte Count; D008099:Liver / Q000187:drug effects / Q000201:enzymology; D008214:Lymphocytes; D008744:Methylamines / Q000494:pharmacology / Q000633:toxicity; D009000:Monocytes; D009504:Neutrophils; D009574:Nitro Compounds / Q000494:pharmacology / Q000633:toxicity; D010087:Oxides / Q000494:pharmacology / Q000633:toxicity; D011437:Propylamines / Q000494:pharmacology / Q000633:toxicity; D011817:Rabbits; D051381:Rats; D013997:Time Factors
D000166:Acridines; D000970:Antineoplastic Agents; D006454:Hemoglobins; D008744:Methylamines; D009574:Nitro Compounds; D010087:Oxides; D011437:Propylamines